These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3393746)

  • 1. [General and local hormonal therapy in scleroderma].
    Dobrescu A; Petrescu Z; Martinescu E; Costinescu M; Vasilca A; Popescu E; Rotaru L; Tăranu T; Pavelescu DM
    Rev Med Chir Soc Med Nat Iasi; 1988; 92(1):145-9. PubMed ID: 3393746
    [No Abstract]   [Full Text] [Related]  

  • 2. [Piascledine in the treatment of scleroderma].
    Szczepański A; Dabrowska H; Moskalewska K
    Przegl Dermatol; 1974; 61(4):525-7. PubMed ID: 4849404
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic effectiveness of ultrasonics and lidase phonophoresis in various forms of scleroderma].
    Didenko IG
    Vestn Dermatol Venerol; 1978 Jun; (6):76-9. PubMed ID: 354249
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of piascledine treatment of scleroderma].
    Szczepański A; Dabrowska H; Moskalewska K
    Przegl Dermatol; 1975; 62(4):555-8. PubMed ID: 1162105
    [No Abstract]   [Full Text] [Related]  

  • 5. Stimulating circulation to end stasis in scleroderma.
    Yuan X; Li JD; Chen WJ; Li ZS; Zhu HT; Liu JW; Zhu MJ
    Chin Med J (Engl); 1981 Feb; 94(2):85-93. PubMed ID: 6786844
    [No Abstract]   [Full Text] [Related]  

  • 6. [The course of scleroderma following treatment with carnitin].
    Nitzschner H
    Dermatol Monatsschr; 1974 Jul; 160(7):592-6. PubMed ID: 4411133
    [No Abstract]   [Full Text] [Related]  

  • 7. [Morphological changes in the skin in scleroderma in the process of treatment with unithiol].
    Dubinskiĭ AA; Tseraidis GS; Guĭda PP; Petrusenko EA; Babykina EA
    Vrach Delo; 1978 Oct; (10):112-4. PubMed ID: 716343
    [No Abstract]   [Full Text] [Related]  

  • 8. [Proteolytic enzyme, trypsin, in therapy of patients with scleroderma].
    Dovzhanskiĭ SI; Slesarenko NA
    Vestn Dermatol Venerol; 1977 Aug; (8):56-8. PubMed ID: 930311
    [No Abstract]   [Full Text] [Related]  

  • 9. [Madecassol in the treatment of scleroderma (preliminary study)].
    Szczepański A; Dabrowska H; Blaszczyk M
    Przegl Dermatol; 1974; 61(5):701-3. PubMed ID: 4419170
    [No Abstract]   [Full Text] [Related]  

  • 10. Salazopyrin (azulfidine) treatment in scleroderma.
    Dover N
    Isr J Med Sci; 1971 Nov; 7(11):1301-3. PubMed ID: 4400695
    [No Abstract]   [Full Text] [Related]  

  • 11. PUVA treatment in sclerodermatoid spectrum of dermatologic diseases: our initial experience.
    Baum S; Pavlotsky F; Shpiro D; Trau H
    Isr Med Assoc J; 2004 Sep; 6(9):563-4. PubMed ID: 15373320
    [No Abstract]   [Full Text] [Related]  

  • 12. [Observations of the course of scleroderma after combined Hylase-carnitine therapy].
    Nitzschner H
    Z Arztl Fortbild (Jena); 1975 Nov; 69(21):1108. PubMed ID: 1226844
    [No Abstract]   [Full Text] [Related]  

  • 13. [Trafuril reaction in scleroderma].
    Urban J
    Przegl Dermatol; 1976; (6 Suppl):367-9. PubMed ID: 1032188
    [No Abstract]   [Full Text] [Related]  

  • 14. [Use of Tebessal in scleroderma].
    Mattos O; de Oliveira Neto MP
    Rev Bras Med; 1972 Mar; 29(3):139-40. PubMed ID: 5033154
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapeutic effectiveness of treatment of patients with scleroderma at the Pyatigorsk Spa].
    Braĭtsev AV; Kessel' VP; Marzeeva GI; Shliapak EA; Angelova VS
    Vestn Dermatol Venerol; 1971 Oct; 45(10):35-9. PubMed ID: 5134075
    [No Abstract]   [Full Text] [Related]  

  • 16. [Scleroderma and esophageal changes: treatment and instrumental control].
    Altomare GF; Allara A; Pigatto PD
    G Ital Dermatol Venereol; 1984; 119(4):263-6. PubMed ID: 6490099
    [No Abstract]   [Full Text] [Related]  

  • 17. [Characteristics of the course of scleroderma in diabetes mellitus].
    Khamaganova IV
    Sov Med; 1990; (2):72-6. PubMed ID: 2356535
    [No Abstract]   [Full Text] [Related]  

  • 18. [Dynamics of hydroxyproline content as the indicator of the severity of the course and the effectiveness of treatment of focal scleroderma].
    Fedorova EG; Lashmanova AP
    Vestn Dermatol Venerol; 1978 Dec; (12):18-22. PubMed ID: 570330
    [No Abstract]   [Full Text] [Related]  

  • 19. Scleroderma--developing measures of response.
    Furst DE; Khanna D; Mattucci-Cerinic M; Silman AJ; Merkel PA; Foeldvari I;
    J Rheumatol; 2005 Dec; 32(12):2477-80. PubMed ID: 16331791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Histomorphologic and histochemical changes in the skin during the treatment of scleroderma].
    Sych LI; Trofimova LIa
    Vestn Dermatol Venerol; 1971; 45(3):22-6. PubMed ID: 5122538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.